4 - Fortrea Holdings Inc. (0001965040) (Issuer)

4 - Fortrea Holdings Inc. (0001965040) (Issuer)

Jefferies downgraded Fortrea from Buy to Hold and set a new price target of $21.00 from $25.00 previously

Evercore ISI downgraded Fortrea from Outperform to In-line and set a new price target of $27.00 from $31.00 previously

Barclays resumed coverage of Fortrea with a rating of Equal Weight and set a new price target of $30.00

Goldman initiated coverage of Fortrea with a rating of Neutral and set a new price target of $28.00

TD Cowen initiated coverage of Fortrea with a rating of Hold and set a new price target of $27.00

Mizuho initiated coverage of Fortrea with a rating of Neutral and set a new price target of $27.00

Robert W. Baird initiated coverage of Fortrea with a rating of Neutral and set a new price target of $43.00

Deutsche Bank initiated coverage of Fortrea with a rating of Hold and set a new price target of $36.00

William Blair initiated coverage of Fortrea with a rating of Mkt Perform

Jefferies initiated coverage of Fortrea with a rating of Buy and set a new price target of $44.00

SC 13G - Fortrea Holdings Inc. (0001965040) (Subject)

SC 13D/A - Fortrea Holdings Inc. (0001965040) (Subject)

SC 13D/A - Fortrea Holdings Inc. (0001965040) (Subject)

For the three months ended September 30, 2024, from continuing operations: Revenues of $674.9 millionGAAP net loss of $(18.5) millionAdjusted EBITDA of $64.2 millionGAAP and adjusted net income (loss) per diluted share of $(0.21) and $0.23, respectivelyBook-to-bill ratio of 1.23x, resulting in 1.15x book-to-bill for the trailing 12 months DURHAM, N.C., Nov. 08, 2024 (GLOBE NEWSWIRE) -- Fortrea (NASDAQ:FTRE) (the "Company"), a leading global contract research organization ("CRO"), today reported financial results for the third quarter ended September 30, 2024. "We had a solid quarter of execution" said Tom Pike, chairman and CEO of Fortrea. "Our book-to-bill ratio for the quarter, as exp

DURHAM, N.C., Oct. 14, 2024 (GLOBE NEWSWIRE) -- Fortrea (NASDAQ:FTRE) (the "Company"), a leading global contract research organization ("CRO"), today announced that it will release its third quarter 2024 financial results before the market opens on Friday, November 8, 2024. Fortrea will host a conference call at 8:00 am ET that day to review its financial results and conduct a question-and-answer session. To participate in the earnings call, participants should register online at the Fortrea Investor Relations website. To avoid potential delays, please join at least 10 minutes prior to the start of the call. The conference call can also be accessed through the following earnings webcast l

For the three months ended June 30, 2024, from continuing operations: Revenues of $662.4 millionGAAP net loss of $(99.3) millionAdjusted EBITDA of $55.2 millionGAAP and adjusted diluted loss per share of $(1.11) and $(0.03), respectivelyBook-to-bill ratio of 0.96x, resulting in 1.16x book-to-bill for the trailing 12 monthsCompleted divestiture of assets relating to the Endpoint Clinical and Patient Access businessesDebt paydown of $504 million in the quarter using initial divestiture and securitization proceedsRevised full-year guidance DURHAM, N.C., Aug. 12, 2024 (GLOBE NEWSWIRE) -- Fortrea (NASDAQ:FTRE) (the "Company"), a leading global contr

DURHAM, N.C., July 17, 2024 (GLOBE NEWSWIRE) -- Fortrea (NASDAQ:FTRE) (the "Company"), a leading global contract research organization (CRO), today announced that it will release its second quarter 2024 financial results before the market opens on Monday, August 12, 2024. Fortrea will host a conference call at 9:00 am ET that day to review its financial results and conduct a question-and-answer session. To participate in the earnings call, participants should register online at the Fortrea Investor Relations website. To avoid potential delays, please join at least 10 minutes prior to the start of the call. The conference call can also be accessed through the following earnings webcast lin

DURHAM, N.C., July 11, 2024 (GLOBE NEWSWIRE) -- Fortrea (NASDAQ:FTRE), a leading global contract research organization (CRO), today announced that Robert "Bobby" Parks has been appointed as chief accounting officer (CAO), responsible for Fortrea's accounting function, including financial reporting, risk, controls and compliance in accordance with applicable standards, laws and regulations. "We are pleased to welcome Bobby to the Fortrea team, bringing his broad and deep experience from CROs and other fast-paced environments," said Fortrea Chief Financial Officer Jill McConnell. "Bobby has a track record of managing Sarbanes-Oxley Act requirements and internal controls, including for CROs,

DURHAM, N.C., June 27, 2024 (GLOBE NEWSWIRE) -- Fortrea (NASDAQ:FTRE), a leading global contract research organization (CRO), today announced the launch of its artificial intelligence (AI) Innovation Studio, signaling a strategic investment in reshaping the execution of clinical trials today and into the future. The studio will develop and deploy AI and machine learning (ML) technologies to drive speed, agility, quality and enhanced patient safety in the clinical research process by equipping and empowering people to focus on the critical human element of clinical trials. "Patients around the world are waiting for novel, life-changing treatments. With AI, we now have the power—and the ob

DURHAM, N.C., June 19, 2024 (GLOBE NEWSWIRE) -- Fortrea (NASDAQ:FTRE), a leading global contract research organization (CRO), today announced that Chief Financial Officer Jill McConnell will participate in a virtual fireside chat hosted by Elizabeth Anderson, senior managing director at Evercore ISI, to discuss Fortrea's business on Thursday, June 20, 2024 at 2:00 pm ET. Webcast and Replay Information Registration for the live event is required here. The event is scheduled for 30 minutes. A replay will be available by accessing the Fortrea Investor Relations website after the conclusion of the event. About Fortrea Fortrea (NASDAQ:FTRE) is a leading global provider of clinical developme

DURHAM, N.C., June 04, 2024 (GLOBE NEWSWIRE) -- Fortrea (NASDAQ:FTRE) a leading global contract research organization ("CRO"), today announced it has completed the divestiture of assets relating to its Enabling Services segment, namely its Endpoint Clinical ("Endpoint") and Fortrea Patient Access ("FPA") businesses, to Arsenal Capital Partners ("Arsenal"), a leading private equity firm specializing in building market-leading, technology-rich healthcare and industrial growth companies. Endpoint and FPA provide best-in-class Randomization and Trial Supply Management (RTSM) and patient access solutions respectively. They both represent strategically differentiated entry points within the pha

DURHAM, N.C., June 03, 2024 (GLOBE NEWSWIRE) -- Fortrea (NASDAQ:FTRE), a leading global contract research organization (CRO), today announced that Chairman and Chief Executive Officer, Tom Pike and Chief Financial Officer, Jill McConnell will present at the Jefferies Global Healthcare Conference on Wednesday, June 5, 2024 at 11:00 am ET. The live webcast will be available to investors and other interested parties by accessing the Fortrea Investor Relations website. A webcast replay will be available after the conclusion of the event. About Fortrea Fortrea (NASDAQ:FTRE) is a leading global provider of clinical development and patient access solutions to the life sciences industry.

DURHAM, N.C., May 30, 2024 (GLOBE NEWSWIRE) -- Fortrea (NASDAQ:FTRE) (the "Company"), a leading global contract research organization (CRO), today announced its comprehensive and integrated solution to improve the diversity and inclusion (D&I) of participants in clinical trials. Fortrea's D&I solution is designed to expand patient access to participate in clinical trials and address the U.S. Food and Drug Administration (FDA) requirements, under The Food and Drug Omnibus Reform Act, to increase enrollment of underrepresented populations in clinical trials. Fortrea's comprehensive process integrates five components of diversity action planning and execution: Real-world evidence advisors r

For the three months ended September 30, 2024, from continuing operations: Revenues of $674.9 millionGAAP net loss of $(18.5) millionAdjusted EBITDA of $64.2 millionGAAP and adjusted net income (loss) per diluted share of $(0.21) and $0.23, respectivelyBook-to-bill ratio of 1.23x, resulting in 1.15x book-to-bill for the trailing 12 months DURHAM, N.C., Nov. 08, 2024 (GLOBE NEWSWIRE) -- Fortrea (NASDAQ:FTRE) (the "Company"), a leading global contract research organization ("CRO"), today reported financial results for the third quarter ended September 30, 2024. "We had a solid quarter of execution" said Tom Pike, chairman and CEO of Fortrea. "Our book-to-bill ratio for the quarter, as exp

DURHAM, N.C., Oct. 14, 2024 (GLOBE NEWSWIRE) -- Fortrea (NASDAQ:FTRE) (the "Company"), a leading global contract research organization ("CRO"), today announced that it will release its third quarter 2024 financial results before the market opens on Friday, November 8, 2024. Fortrea will host a conference call at 8:00 am ET that day to review its financial results and conduct a question-and-answer session. To participate in the earnings call, participants should register online at the Fortrea Investor Relations website. To avoid potential delays, please join at least 10 minutes prior to the start of the call. The conference call can also be accessed through the following earnings webcast l

For the three months ended June 30, 2024, from continuing operations: Revenues of $662.4 millionGAAP net loss of $(99.3) millionAdjusted EBITDA of $55.2 millionGAAP and adjusted diluted loss per share of $(1.11) and $(0.03), respectivelyBook-to-bill ratio of 0.96x, resulting in 1.16x book-to-bill for the trailing 12 monthsCompleted divestiture of assets relating to the Endpoint Clinical and Patient Access businessesDebt paydown of $504 million in the quarter using initial divestiture and securitization proceedsRevised full-year guidance DURHAM, N.C., Aug. 12, 2024 (GLOBE NEWSWIRE) -- Fortrea (NASDAQ:FTRE) (the "Company"), a leading global contr

DURHAM, N.C., July 17, 2024 (GLOBE NEWSWIRE) -- Fortrea (NASDAQ:FTRE) (the "Company"), a leading global contract research organization (CRO), today announced that it will release its second quarter 2024 financial results before the market opens on Monday, August 12, 2024. Fortrea will host a conference call at 9:00 am ET that day to review its financial results and conduct a question-and-answer session. To participate in the earnings call, participants should register online at the Fortrea Investor Relations website. To avoid potential delays, please join at least 10 minutes prior to the start of the call. The conference call can also be accessed through the following earnings webcast lin

For the three months ended March 31, 2024, from continuing operations: Revenues of $662.1 millionGAAP net loss of $81.6 millionAdjusted EBITDA of $29.5 millionGAAP and adjusted diluted earnings (loss) per share of $(0.91) and $(0.04), respectivelyBook-to-bill ratio of 1.11x, resulting in >1.2x book-to-bill for the trailing nine monthsPlanned divestiture of assets relating to the Endpoint Clinical and Patient Access businesses on track DURHAM, N.C., May 13, 2024 (GLOBE NEWSWIRE) -- Fortrea (NASDAQ:FTRE) (the "Company"), a leading global contract research organization (CRO), today reported financial results for the first quarter ended March 31, 2024. "We are making solid progress toward o

DURHAM, N.C., May 06, 2024 (GLOBE NEWSWIRE) -- Fortrea (NASDAQ:FTRE) (the "Company"), a leading global contract research organization (CRO), today announced an updated issuance date for the company's first quarter 2024 financial results. The Company requires additional time to work through accounting and discontinued operations matters primarily as a result of entering into a definitive agreement in March 2024 to divest assets relating to the Company's Enabling Services segment. Fortrea will now release its first quarter 2024 financial results before the market opens on Monday, May 13, 2024, rather than on Tuesday, May 7, 2024, as previously announced. The company will host a conference c

DURHAM, N.C., April 11, 2024 (GLOBE NEWSWIRE) -- Fortrea (NASDAQ:FTRE) (the "Company"), a leading global contract research organization (CRO), today announced that it will release its first quarter 2024 financial results before the market opens on Tuesday, May 7, 2024. Fortrea will host a conference call at 9:00 am ET that day to review its financial results and conduct a question-and-answer session. To participate in the earnings call, participants should register online at the Fortrea Investor Relations website. To avoid potential delays, please join at least 10 minutes prior to the start of the call. The conference call can also be accessed through the following earnings webcast link.

For the three months and full year ended December 31, 2023: Revenues of $775.4 million for the fourth quarter, $3,109.0 million for the full yearGAAP net loss of $(36.0) million for the fourth quarter, $(3.4) million for the full yearAdjusted EBITDA of $67.2 million for the fourth quarter, $267.3 million for the full yearFourth-quarter book-to-bill ratio of 1.30x DURHAM, N.C., March 11, 2024 (GLOBE NEWSWIRE) -- Fortrea (NASDAQ:FTRE) (the "Company"), a leading global contract research organization (CRO), today reported financial results for the fourth quarter and full year ended December 31, 2023. "Fortrea successfully navigated the second half 2023 transforming a "division of a divisi

Proposed divestiture of Endpoint Clinical and Fortrea Patient Access businesses further streamlines Fortrea's strategic focus as a pure-play contract research organization Creates standalone best-in-class Randomization and Trial Supply Management and Patient Access solutions positioned for differentiation and growth DURHAM, N.C., March 11, 2024 (GLOBE NEWSWIRE) -- Fortrea (NASDAQ:FTRE) (the "Company"), a leading global contract research organization (CRO), today announced it has signed a definitive agreement to divest assets relating to its Enabling Services segment, namely its Endpoint Clinical ("Endpoint") and Fortrea Patient Access businesses, to Arsenal Capital Partners ("Arsenal"),

DURHAM, N.C., Jan. 29, 2024 (GLOBE NEWSWIRE) -- Fortrea (NASDAQ:FTRE) (the "Company"), a leading global contract research organization (CRO), today announced that it will release its fourth quarter and full year 2023 financial results before the market opens on Monday, March 11, 2024. Fortrea will host a conference call at 9:00 am ET that day to review its financial results and conduct a question-and-answer session. To participate in the earnings call, participants should register online at the Fortrea Investor Relations website. To avoid potential delays, please join at least 10 minutes prior to the start of the call. The conference call can also be accessed through the following earning

Barclays analyst Luke Sergott reinstates Fortrea Holdings (NASDAQ:FTRE) with a Equal-Weight and announces $30 price target.

Across the recent three months, 8 analysts have shared their insights on Fortrea Holdings (NASDAQ:FTRE), expressing a variety of opinions spanning from bullish to bearish. The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 0 2 4 2 0 Last 30D 0 0 0 1 0 1M Ago 0 0 0 0 0 2M Ago 0 0 4 0 0 3M Ago 0 2 0 1 0 Analysts have set 12-month price targets for Fortrea Holdings, revealing an average target of $28.75, a high estimate of $36.00, and a low estimate of $26.00. Highlighting a 21.87% decrease

B of A Securities analyst Derik De Bruin maintains Fortrea Holdings (NASDAQ:FTRE) with a Underperform and lowers the price target from $27 to $26.

During the last three months, 9 analysts shared their evaluations of Fortrea Holdings (NASDAQ:FTRE), revealing diverse outlooks from bullish to bearish. The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 0 2 5 2 0 Last 30D 0 0 1 0 0 1M Ago 0 2 3 1 0 2M Ago 0 0 0 0 0 3M Ago 0 0 1 1 0 Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $31.11, with a high estimate of $43.00 and a low estimate of $27.00. This current average represents a 16.37% de

Goldman Sachs analyst Matthew Sykes initiates coverage on Fortrea Holdings (NASDAQ:FTRE) with a Neutral rating and announces Price Target of $28.

TD Cowen analyst Charles Rhyee initiates coverage on Fortrea Holdings (NASDAQ:FTRE) with a Hold rating and announces Price Target of $27.

Mizuho analyst Ann Hynes initiates coverage on Fortrea Holdings (NASDAQ:FTRE) with a Neutral rating and announces Price Target of $27.

Deutsche Bank analyst Justin Bowers maintains Fortrea Holdings (NASDAQ:FTRE) with a Hold and lowers the price target from $36 to $28.

B of A Securities analyst Derik De Bruin maintains Fortrea Holdings (NASDAQ:FTRE) with a Underperform and lowers the price target from $33 to $27.

SCHEDULE 13G - Fortrea Holdings Inc. (0001965040) (Subject)

10-Q - Fortrea Holdings Inc. (0001965040) (Filer)

8-K - Fortrea Holdings Inc. (0001965040) (Filer)

8-K/A - Fortrea Holdings Inc. (0001965040) (Filer)

10-Q - Fortrea Holdings Inc. (0001965040) (Filer)

8-K - Fortrea Holdings Inc. (0001965040) (Filer)

8-K - Fortrea Holdings Inc. (0001965040) (Filer)

8-K - Fortrea Holdings Inc. (0001965040) (Filer)

8-K/A - Fortrea Holdings Inc. (0001965040) (Filer)

8-K - Fortrea Holdings Inc. (0001965040) (Filer)